REFERENCES
1. Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37-49.
2. Geneva: World Health Organization. Global status report on alcohol and health and treatment of substance use disorders. Available from: https://www.who.int/publications/i/item/9789240096745. [Last accessed on 7 Aug 2026].
3. Asrani SK, Mellinger J, Sterling S, et al. Reducing alcohol-associated liver disease burden in the general population. Lancet Gastroenterol Hepatol. 2025;10:1117-31.
4. Rinella ME, Lazarus JV, Ratziu V, et al. ; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
5. Colmenero J, Crespo G, Ntandja Wandji LC, Fundora Y, Louvet A. Steatotic liver disease and liver transplantation: candidate selection and post-transplant management. JHEP Rep. 2026;8:101704.
6. Leggio L, Farokhnia M, Kenny PJ, Pepino MY, Simmons WK. Crosstalk between alcohol use disorder and obesity: two sides of the same coin? Mol Psychiatry 2025;30:5938-52.
7. Han B, Jones CM, Einstein EB, Powell PA, Compton WM. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. JAMA Psychiatry. 2021;78:922-4.
8. Rabiee A, Mahmud N, Falker C, Garcia-Tsao G, Taddei T, Kaplan DE. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis. Hepatol Commun. 2023;7:e0093.
9. Mantovani A, Morandin R, Fiorio V, et al. Glucagon-like peptide-1 receptor agonists improve MASH and liver fibrosis: a meta-analysis of randomised controlled trials. Liver Int. 2025;45:e70256.
10. Sanyal AJ, Newsome PN, Kliers I, et al. ; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
11. Gonzalez-Rellan MJ, Riobello C, Fang S, et al. The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. Cell Metab. 2026;38:1334-53.e7.
12. Amorim Moreira Alves G, Teranishi M, Teixeira de Castro Gonçalves Ortega AC, James F, Perera Molligoda Arachchige AS. Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights. Med Sci. 2025;13:136.
13. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7:e159863.
14. Probst L, Monnerat S, Vogt DR, et al. Effects of dulaglutide on alcohol consumption during smoking cessation. JCI Insight. 2023;8:e170419.
15. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82:395-405.
16. Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407:1687-98.
17. Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82:94-8.
18. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun. 2024;15:4548.
19. Rashid Z, Woldesenbet S, Khalil M, et al. Impact of GLP-1RA on the risk of adverse liver outcomes among patients with alcohol-associated liver disease and type 2 diabetes. Liver Int. 2025;45:e16132.
20. Kuo CC, Chuang MH, Li CH, et al. Glucagon-like peptide-1 receptor agonists and liver outcomes in patients with MASLD and type 2 diabetes. Aliment Pharmacol Ther. 2025;61:1163-74.
21. Singal AK, Leggio L. GLP-1 receptor agonists in alcohol use disorder and alcohol-associated liver disease. Lancet Gastroenterol Hepatol. 2025;10:707-9.
22. Jensen EL, Thiele M, Torp N, et al. Fibrosis progression rate and comparison of paired liver biopsy versus non-invasive tests as surrogate endpoints for clinical trials in MetALD and ALD. Clin Gastroenterol Hepatol. 2026.
23. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158:1789-95.
24. Vaz J, Nasr P, Helander A, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025;83:1011-22.
25. Arab JP, Díaz LA, Rehm J, et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025;82:744-56.
